Does PDE8B rs4704397 AA raise TSH while FOXE1 rs965513 AA does not?

The hypothalamic-pituitary-thyroid (HPT) axis maintains systemic thyroid hormone homeostasis through a tightly regulated feedback loop. Common genetic variations in the PDE8B and FOXE1 genes act as constitutional tuners of this system, though they alter the homeostatic set point in opposing directions.

Clinical and genetic evidence

• PDE8B rs4704397 AA: Large-scale genome-wide association studies (GWAS) demonstrate that this genotype is robustly associated with an elevated baseline TSH set point and slightly lower free T4 levels, shifting the clinical index upward.
• FOXE1 rs965513 AA: Conversely, population-scale data show that this variant is associated with lower circulating TSH and lower free T4 levels, meaning it does not bias TSH higher.

Mechanistic pathways

• Intracellular cAMP regulation: The PDE8B gene encodes a high-affinity, cAMP-specific phosphodiesterase in thyroid follicular cells. The rs4704397 A allele is linked to increased PDE8B expression and activity, which accelerates the degradation of intracellular cAMP.
• Blunted TSH responsiveness: This rapid cAMP breakdown blunts the thyroid's intracellular signaling cascade downstream of the TSH receptor, reducing downstream thyroid hormone synthesis.
• Compensatory HPT-axis adjustment: To maintain adequate thyroid hormone output despite this blunted sensitivity, the HPT axis compensates via negative feedback by secreting more TSH, resetting the baseline feedback loop to a higher TSH set point.
• FOXE1 transcriptional regulation: The FOXE1 rs965513 AA genotype decreases the expression of FOXE1 and the TSH receptor (TSHR), altering the feedback loop and dampening thyroid differentiation, which ultimately drives circulating TSH levels downward rather than upward.

Bottom line

• The claim is partially supported: only the PDE8B rs4704397 AA genotype biases baseline TSH higher (via accelerated cAMP degradation and blunted thyroidal sensitivity), whereas the FOXE1 rs965513 AA genotype actually shifts the HPT-axis set point downward, resulting in lower circulating TSH levels.